LENVATINIB

Search structure
Synonyms:
Status: Approved (2015)
Entry Type: Small molecule
Molecule Category: Parent
ATC: L01EX08
UNII: EE083865G2

Structure
InChI Key WOSKHXYHFSIKNG-UHFFFAOYSA-N
Smile COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
InChI
InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H19ClN4O4
Molecular Weight 426.86
AlogP 4.07
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 6.0
Polar Surface Area 115.57
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Pharmacology

Primary Target
fms related receptor tyrosine kinase 4
kinase insert domain receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Ret family
- 10 - 2 -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase VEGFR family
- 1-4 2 - -
Enzyme Lyase
- - - 133 -
Other cytosolic protein
- 10 - - -
Unclassified protein
- 10 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Thyroid Neoplasms 4 D013964 ClinicalTrials
Thyroid Neoplasms 4 D013964 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Colorectal Neoplasms 3 D015179 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Carcinoma, Squamous Cell 3 D002294 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Carcinoma, Renal Cell 3 D002292 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Glioma 2 D005910 ClinicalTrials
Carcinoma, Adenoid Cystic 2 D003528 ClinicalTrials
Adenocarcinoma, Follicular 2 D018263 ClinicalTrials
Adenocarcinoma of Lung 2 D000077192 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Mesothelioma 2 D008654 ClinicalTrials
Osteosarcoma 2 D012516 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Neuroendocrine Tumors 2 D018358 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Adenocarcinoma 2 D000230 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Meningeal Carcinomatosis 2 D055756 ClinicalTrials
Carcinoma, Neuroendocrine 2 D018278 ClinicalTrials
Small Cell Lung Carcinoma 2 D055752 ClinicalTrials
Carcinoma, Merkel Cell 2 D015266 ClinicalTrials
Ovarian Neoplasms 1 D010051 ClinicalTrials
Kidney Diseases 1 D007674 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 1 D064129 ClinicalTrials
Rectal Neoplasms 1 D012004 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials

Related Entries

Scaffolds

Salt

Cross References

Resources Reference
CAS NUMBER 417716-92-8
ChEBI 85994
ChEMBL CHEMBL1289601
DrugBank DB09078
DrugCentral 4942
EPA CompTox DTXSID50194605
FDA SRS EE083865G2
Guide to Pharmacology 7426
PDB LEV
PharmGKB PA166153472
PubChem 9823820
SureChEMBL SCHEMBL864638
ZINC ZINC000003816292
CONTENTS